WMT

83.09

-4.79%↓

COST

915

-5.49%↓

TGT

95.77

+1.54%↑

KR

67.14

-4.98%↓

GIS

59.55

-2.39%↓

WMT

83.09

-4.79%↓

COST

915

-5.49%↓

TGT

95.77

+1.54%↑

KR

67.14

-4.98%↓

GIS

59.55

-2.39%↓

WMT

83.09

-4.79%↓

COST

915

-5.49%↓

TGT

95.77

+1.54%↑

KR

67.14

-4.98%↓

GIS

59.55

-2.39%↓

WMT

83.09

-4.79%↓

COST

915

-5.49%↓

TGT

95.77

+1.54%↑

KR

67.14

-4.98%↓

GIS

59.55

-2.39%↓

WMT

83.09

-4.79%↓

COST

915

-5.49%↓

TGT

95.77

+1.54%↑

KR

67.14

-4.98%↓

GIS

59.55

-2.39%↓

Search

Hims & Hers Health Inc

Gesloten

SectorConsumenten defensie

25.95 -7.06

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

23.9

Max

26.98

Belangrijke statistieken

By Trading Economics

Inkomsten

-50M

26M

Verkoop

80M

481M

K/W

Sectorgemiddelde

54.722

44.466

EPS

0.227

Winstmarge

5.409

Werknemers

1,637

EBITDA

-8.2M

19M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+66.13% upside

Dividenden

By Dow Jones

Volgende Winsten

5 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-4.7B

6.5B

Vorige openingsprijs

33.01

Vorige sluitingsprijs

25.95

Nieuwssentiment

By Acuity

50%

50%

60 / 152 Rangschikking in Consumer defensive

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Hims & Hers Health Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 apr 2025, 22:38 UTC

Populaire aandelen

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1 apr 2025, 23:15 UTC

Belangrijke Marktbewegers

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25 feb 2025, 15:33 UTC

Belangrijke Marktbewegers

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18 nov 2024, 19:07 UTC

Belangrijke Marktbewegers

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14 okt 2024, 15:02 UTC

Belangrijke Marktbewegers

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

3 okt 2024, 11:28 UTC

Belangrijke Marktbewegers

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

2 apr 2025, 16:53 UTC

Top Nieuws

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19 mrt 2025, 15:54 UTC

Top Nieuws

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21 feb 2025, 23:20 UTC

Winsten

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10 feb 2025, 12:00 UTC

Top Nieuws

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19 dec 2024, 17:16 UTC

Top Nieuws

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19 dec 2024, 15:14 UTC

Top Nieuws

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19 dec 2024, 15:02 UTC

Top Nieuws

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16 dec 2024, 13:47 UTC

Top Nieuws

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16 dec 2024, 07:00 UTC

Top Nieuws

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3 okt 2024, 14:45 UTC

Top Nieuws

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3 okt 2024, 13:12 UTC

Top Nieuws

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 okt 2024, 11:45 UTC

Top Nieuws

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 okt 2024, 10:14 UTC

Top Nieuws

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2 aug 2024, 17:52 UTC

Acquisities, Fusies, Overnames

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

26 jun 2024, 11:00 UTC

Top Nieuws
Acquisities, Fusies, Overnames

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

24 mei 2024, 20:37 UTC

Winsten

The Score: Target, Nvidia, Live Nation and More Stocks That Defined the Week -- WSJ

Peer Vergelijking

Prijswijziging

Hims & Hers Health Inc Prognose

Koersdoel

By TipRanks

66.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 46.5 USD  66.13%

Hoogste 85 USD

Laagste 21 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Hims & Hers Health Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

13 ratings

5

Buy

6

Hold

2

Sell

Technische score

By Trading Central

N/A / 31.88Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

60 / 152 Rangschikking in Consumenten defensie

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.